Burstein HJ et al. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2023;41(18):3423-5. Abstract

Giridhar K et al. ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2‑) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study. ESMO Breast Cancer 2024;Abstract 51P.

Lloyd MR et al. Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). ASCO 2024;Abstract 1071.

Wander SA, Bardia A. Cracking the genomic code of CDK4/6 inhibitor resistance. Clin Cancer Res 2024;30(10):2008-10. Abstract